Literature DB >> 25141276

Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Mary Dawn T Co1, Masanori Terajima, Stephen J Thomas, Richard G Jarman, Kamonthip Rungrojcharoenkit, Stefan Fernandez, In-Kyu Yoon, Darunee Buddhari, John Cruz, Francis A Ennis.   

Abstract

The hemagglutination inhibition (HAI) antibody titer is considered the primary immune correlate of protection for influenza. However, recent studies have highlighted the limitations on the use of the HAI titer as a correlate in at-risk populations such as children and older adults. In addition to the neutralization of cell-free virus by antibodies to hemagglutinin and interference of virus release from infected cells by antibodies to neuraminidase, influenza virus-specific antibodies specifically can bind to infected cells and lyse virus-infected cells through the activation of complement or natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent lysis (CDL). We evaluated preexisting HAI, CDL, and ADCC antibodies in young children enrolled in a prospective cohort study of dengue during the epidemic with influenza A(H1N1)pdm09 virus to determine associations between preexisting antibodies and the occurrence of clinical or subclinical influenza virus infection. Though both preexisting HAI and CDL antibodies were associated with protection against clinical influenza, our data suggested that CDL was not a better correlate than HAI. We found that ADCC antibodies behaved differently from HAI and CDL antibodies. Unlike HAI and CDL antibodies, preexisting ADCC antibodies did not correlate with protection against clinical influenza. In fact, ADCC antibodies were detected more frequently in the clinical influenza group than the subclinical group. In addition, in contrast to HAI and CDL antibodies, HAI and the ADCC antibodies titers did not correlate. We also found that ADCC, but not CDL or HAI antibodies, positively correlated with the ages of the children.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25141276      PMCID: PMC4183906          DOI: 10.1089/vim.2014.0061

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  30 in total

1.  Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells.

Authors:  P G Hughey; R W Compans; S L Zebedee; R A Lamb
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

Authors:  Suzanne L Epstein
Journal:  J Infect Dis       Date:  2005-11-21       Impact factor: 5.226

Review 3.  Humoral immunity to HIV-1: neutralization and beyond.

Authors:  M Huber; A Trkola
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

4.  Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection.

Authors:  S Kohl; M S West; C G Prober; W M Sullender; L S Loo; A M Arvin
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

5.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.

Authors:  R A Lamb; S L Zebedee; C D Richardson
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

6.  Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

7.  Neutralization and infection-enhancement epitopes of influenza A virus hemagglutinin.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

8.  Measles virus-specific functional antibody responses and viremia during acute measles.

Authors:  D N Forthal; G Landucci; A Habis; M Zartarian; J Katz; J G Tilles
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

9.  Expression of influenza A virus internal antigens on the surface of infected P815 cells.

Authors:  J W Yewdell; E Frank; W Gerhard
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

10.  Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination.

Authors:  S Vella; G Rocchi; S Resta; M Marcelli; A De Felici
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

View more
  26 in total

1.  Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge.

Authors:  Sinthujan Jegaskanda; Catherine Luke; Heather D Hickman; Mark Y Sangster; Wendy F Wieland-Alter; Jacqueline M McBride; Jon W Yewdell; Peter F Wright; John Treanor; Carrie M Rosenberger; Kanta Subbarao
Journal:  J Infect Dis       Date:  2016-06-28       Impact factor: 5.226

2.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Authors:  Wenqian He; Gene S Tan; Caitlin E Mullarkey; Amanda J Lee; Mannie Man Wai Lam; Florian Krammer; Carole Henry; Patrick C Wilson; Ali A Ashkar; Peter Palese; Matthew S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

3.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Authors:  Katie L Winarski; Juanjie Tang; Laura Klenow; Jeehyun Lee; Elizabeth M Coyle; Jody Manischewitz; Hannah L Turner; Kazuyo Takeda; Andrew B Ward; Hana Golding; Surender Khurana
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

4.  Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

Authors:  Rory D de Vries; Nella J Nieuwkoop; Fiona R M van der Klis; Marion P G Koopmans; Florian Krammer; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2017-12-27       Impact factor: 5.226

Review 5.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

6.  High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.

Authors:  Masanori Terajima; Mary Dawn T Co; John Cruz; Francis A Ennis
Journal:  J Infect Dis       Date:  2015-03-20       Impact factor: 5.226

7.  Glycosylation of Antigen-Specific Antibodies: Perspectives on Immunoglobulin G Glycosylation in Vaccination and Immunotherapy.

Authors:  Pranay Bharadwaj; Margaret E Ackerman
Journal:  Exp Suppl       Date:  2021

Review 8.  Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.

Authors:  Suzanne L Epstein
Journal:  Am J Epidemiol       Date:  2018-12-01       Impact factor: 4.897

9.  Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.

Authors:  Veronika Chromikova; Jessica Tan; Sadaf Aslam; Arvind Rajabhathor; Maria Bermudez-Gonzalez; Juan Ayllon; Viviana Simon; Adolfo García-Sastre; Bruno Salaun; Raffael Nachbagauer; Florian Krammer
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

10.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.